Biostage Inc. (BSTG)
Our attorneys are investigating customer losses in Biostage, Inc, an investment offered and sold by National Securities Corporation Inc. (NSC) to its retail clients. Previously known as Harvard Apparatus Regenerative Technology, Inc and traded under (HART).
If you have suffered losses in Biostage, Inc, please contact our lawyers for a free and confidential consultation concerning your legal rights and the possibility of recovery.
At Silver Law Group, we know from experience that not every investment recommended and solicited by a stockbroker is suitable and appropriate for the customer. We have seen, particularly in the initial public offering (IPO) space, that investors are often falsely promised high returns and low risk, when in truth the investment is speculative and subject to the loss of principal. Your financial advisor and the securities firm who sells the investment have a legal duty to fully explain the nature of the investment, its inherent risks and the possibility of loss.
Brokers and financial advisors may push risky initial public offerings on unsuspecting investors based upon strong financial incentives, including large commission payouts. Investors in such offerings must realize that these investments are inherently risky and should be considered very carefully before making a decision to invest. Representations made by stockbrokers that such investments are “safe” and “guaranteed” are typically false and are a red flag of possible fraud.National Securities Corporation Inc. Role in the Investment:
In 2015, National Securities Corporation underwrote Biostage, Inc’s stock offering. At the close of the offering, National Securities Corporation raised over 6 million ($6,088,749.00). Biostage, Inc was listed on the Nasdaq under the stock symbol “BSTG”. As of November 13, 2017, Biostage, Inc stock is worth $0.11 per share.
Biostage, Inc Company Profile:
Biostage, Inc. is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.
Biostage is led by Jim McGorry is a life science executive with over thirty years of leadership experience in both medical technology and biotechnology businesses. Most recently Mr. McGorry served as Executive Vice President and General Manager, Translational Oncology Solutions for Champions Oncology and previously was Executive Vice President of Commercial Operations at Accellent.
Silver Law Group represents investment fraud victims in cases to recover their investment losses. If you have questions about your legal rights, please contact Scott Silver of the Silver Law Group for a free consultation at email@example.com or toll-free at (800) 975-4345.